Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.65 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28197598 | 0.92 | NPC1 (0.84) | RAB9ANPC1NR4A2HSD11B1KMT2A | |
| SCHEMBL26584242 | 0.91 | NPC1 (0.82) | RAB9ANPC1HSD11B1KMT2AMEN1 | |
| SCHEMBL315309 | 0.87 | RAB9A (0.69) | RAB9ANPC1NR4A2HSD11B1KMT2A | |
| SCHEMBL10731900 | 0.87 | MEN1 (0.74) | RAB9ANPC1HSD11B1KMT2AMEN1 | |
| SCHEMBL30121738 | 0.86 | NR4A2 (0.85) | RAB9ANPC1NR4A2HSD11B1KMT2A | |
| SCHEMBL719034 | 0.86 | NR4A2 (0.85) | RAB9ANPC1NR4A2HSD11B1KMT2A | |
| SCHEMBL28012695 | 0.84 | NPC1 (0.65) | RAB9ANPC1HSD11B1HTR7LMNA | |
| SCHEMBL659281 | 0.84 | NPC1 (0.59) | RAB9ANPC1NR4A2HSD11B1KMT2A | |
| SCHEMBL13770482 | 0.83 | NPC1 (0.69) | RAB9ANPC1HSD11B1KMT2AMEN1 | |
| SCHEMBL21424286 | 0.82 | KMT2A (0.73) | KMT2AMEN1L3MBTL1CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | CELLGENTEK CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| CN-106966877-B | 1, 4-dicarbonyl compound and preparation method thereof | 郑州大学 | 2020-02-07 | — | — | CN | disclosed |
| US-7488832-B2 | e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488832-B2 | e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488832-B2 | e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1848692-A1 | AZOLYLACYLGUANIDINES AS ß-SECRETASE INHIBITORS | Wyeth (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006088711-A1 | AZOLYLACYLGUANIDINES AS β-SECRETASE INHIBITORS | WYETH (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | BACE1, BACE2, APP | RAB9A 1611/4885NPC1 267/4885NR4A2 2173/4885 |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | BACE1, BACE2, APP | RAB9A 1611/4885NPC1 267/4885NR4A2 2173/4885 |
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | KNTC1, MED1, LEF1 | RAB9A 1996/4885NPC1 601/4885NR4A2 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.